Anti-Human VIPR1 Recombinant Antibody (23A11) (CAT#: TAB-358CQ)

Recombinant monoclonal antibody to VIPR1. The monoclonal antibody is identified as a potent inhibitor of VPAC1 receptor-mediated cAMP production.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Inhib

Figure 1 Light microscopy on day 13 The presence of large proplatelet extrusions arising from the megakaryocytes.

Figure 1 Light microscopy on day 13 The presence of large proplatelet extrusions arising from the megakaryocytes.

Peeters, K., Loyen, S., Van Kerckhoven, S., Stoffels, K., Hoylaerts, M. F., Van Geet, C., & Freson, K. (2010). Thrombopoietic effect of VPAC1 inhibition during megakaryopoiesis. British journal of haematology,  151(1), 54-61.

FC

Figure 2 After 13 d of culture, more CD61+ megakaryocytes were formed in the presence of 23A11 vs. 1C8. A representative FACS plot is shown.

Figure 2 After 13 d of culture, more CD61+ megakaryocytes were formed in the presence of 23A11 vs. 1C8. A representative FACS plot is shown.

Peeters, K., Loyen, S., Van Kerckhoven, S., Stoffels, K., Hoylaerts, M. F., Van Geet, C., & Freson, K. (2010). Thrombopoietic effect of VPAC1 inhibition during megakaryopoiesis. British journal of haematology,  151(1), 54-61.

Neut

Figure 3 After 13 d of culture, more highly polyploid CD61+ megakaryocytes were generated in the presence of the neutralizing anti-VPAC1 Ab 23A11 (black) vs. a control Ab 1C8 (white).

Figure 3 After 13 d of culture, more highly polyploid CD61+ megakaryocytes were generated in the presence of the neutralizing anti-VPAC1 Ab 23A11 (black) vs. a control Ab 1C8 (white).

Peeters, K., Loyen, S., Van Kerckhoven, S., Stoffels, K., Hoylaerts, M. F., Van Geet, C., & Freson, K. (2010). Thrombopoietic effect of VPAC1 inhibition during megakaryopoiesis. British journal of haematology,  151(1), 54-61.


Specifications

  • Immunogen
  • The purified fusion protein GST-VPAC1
  • Host Species
  • Mouse
  • Specificity
  • Human
  • Species Reactivity
  • Human
  • Clone
  • 23A11
  • Applications
  • Inhib, FC, Neut
  • Related Disease
  • Thrombocytopenia

Applications

  • Application Notes
  • This antibody has been tested for use in Inhibition, Flow Cytometry, Neutralization. It's recommended that the optimal antibody concentration, dilution, incubition time, etc. be carefully titrated in specific assays.

Target

  • Alternative Names
  • VIPR1; vasoactive intestinal peptide receptor 1; II; HVR1; RDC1; V1RG; VIPR; VIRG; VAPC1; VPAC1; VPAC1R; VIP-R-1; VPCAP1R; PACAP-R2; PACAP-R-2

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 23A11"

See other products for "VIPR1"

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-358CQ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare